Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 969
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N84ACA70EB6EN
Leaflet:

Download PDF Leaflet

Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Non-Hodgkin Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Non-Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Non-Hodgkin Lymphoma Overview
Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Pipeline Products Glance
Non-Hodgkin Lymphoma - Products under Development by Companies
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Drug Profiles
Non-Hodgkin Lymphoma - Recent Pipeline Updates
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2015
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Agilvax, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Calimmune, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H2 2015
Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Hospira, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H2 2015
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Inventiva SAS, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Vivia Biotech, S.L., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Non-Hodgkin Lymphoma - Dormant Projects, H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products, H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2015

LIST OF FIGURES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2015
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Actelion Ltd
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Agilvax, Inc.
Allinky Biopharma
Altor BioScience Corporation
Amgen Inc.
Arbutus Biopharma Corporation
arGEN-X BV
Astellas Pharma Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
BioAtla, LLC
BioInvent International AB
BioLineRx, Ltd.
Bionovis SA
BioSight Ltd.
Biothera, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calimmune, Inc.
Calithera Biosciences, Inc.
Celgene Corporation
Cell Medica Limited
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Celon Pharma Sp. z o.o.
CerRx, Inc.
Chipscreen Biosciences Ltd
Coherus BioSciences, Inc.
Constellation Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Formula Pharmaceuticals, Inc.
Galderma S.A.
Gamida Cell Ltd.
Gilead Sciences, Inc.
Grupo Ferrer Internacional, S.A.
Hospira, Inc.
iDD biotech SAS
IGF Oncology, LLC.
Immune Design Corp.
ImmunoGen, Inc.
Immunomedics, Inc.
Inbiopro Solutions Pvt. Ltd.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Innate Pharma SA
Innovent Biologics, Inc.
Inventiva SAS
Johnson & Johnson
Juno Therapeutics Inc.
Kainos Medicine, Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
miRagen Therapeutics, Inc.
Mirna Therapeutics, Inc.
MorphoSys AG
Mundipharma International Ltd
NantKwest, Inc.
Neumedicines Inc.
Nordic Nanovector ASA
NovaLead Pharma Pvt. Ltd.
Novartis AG
OncoSec Medical Inc.
Onxeo SA
Onyx Pharmaceuticals, Inc.
Oxford BioTherapeutics Ltd
Panacea Biotec Limited
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
Rhizen Pharmaceuticals S.A.
Richter Gedeon Nyrt.
Sanofi
Sareum Holdings Plc
Seattle Genetics, Inc.
Senhwa Biosciences, Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Henlius Biotech Co., Ltd.
Sigma-Tau S.p.A.
Solasia Pharma K.K.
Soligenix, Inc.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Supratek Pharma Inc.
Taiwan Liposome Company, Ltd.
Targazyme, Inc.
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Limited
TG Therapeutics, Inc.
Theravectys SA
Transgene Biotek Limited
Vivia Biotech, S.L.
Xenetic Biosciences plc
Zymeworks Inc.
Skip to top


Cancer Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 701 pages
Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 588 pages

Ask Your Question

Non-Hodgkin Lymphoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: